The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer.
K. S. Khor
No relevant relationships to disclose
D. Tai
No relevant relationships to disclose
S. Popat
No relevant relationships to disclose
M. Beckles
No relevant relationships to disclose
M. Leung
No relevant relationships to disclose
M. Al Sahaf
No relevant relationships to disclose
E. K. S. Lim
Consultant or Advisory Role - Abbott Laboratories; Strategen
Honoraria - Roche